Medications

Drug boosts survival for women with advanced ovarian cancer

Women with advanced ovarian cancer often face grim statistics, with less than half surviving for five years after their diagnosis. However, a new study suggests that so-called "maintenance therapy" with a targeted cancer ...

Medications

Maintenance immunosuppressive drugs tied to severe COVID-19

Maintenance immunosuppressive drugs are associated with an increased risk for COVID-19 hospitalization in solid organ transplant recipients, according to a study published online Nov. 7 in JAMA Network Open.

Oncology & Cancer

Bortezomib ups response, survival in multiple myeloma

(HealthDay) -- For patients with newly diagnosed multiple myeloma (MM), induction treatment with a combination of bortezomib, doxorubicin, and dexamethasone (PAD) followed by bortezomib maintenance therapy improves complete ...

page 4 from 7